Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.

Although treatment with natalizumab, which was selected as control therapy, increased EZH2 expression by T cells, differences did not reach statistical significance (Fig. 4a ).

also in 111,027 other papers